IL251498B - Indolinone compounds and their uses - Google Patents

Indolinone compounds and their uses

Info

Publication number
IL251498B
IL251498B IL251498A IL25149817A IL251498B IL 251498 B IL251498 B IL 251498B IL 251498 A IL251498 A IL 251498A IL 25149817 A IL25149817 A IL 25149817A IL 251498 B IL251498 B IL 251498B
Authority
IL
Israel
Prior art keywords
indolinone compounds
indolinone
compounds
Prior art date
Application number
IL251498A
Other languages
English (en)
Hebrew (he)
Other versions
IL251498A0 (en
Inventor
Vernier Jean-Michel
Original Assignee
Oncternal Therapeutics Inc
Jean Michel Vernier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics Inc, Jean Michel Vernier filed Critical Oncternal Therapeutics Inc
Publication of IL251498A0 publication Critical patent/IL251498A0/en
Publication of IL251498B publication Critical patent/IL251498B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL251498A 2014-10-09 2017-04-02 Indolinone compounds and their uses IL251498B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062086P 2014-10-09 2014-10-09
PCT/US2015/054533 WO2016057698A1 (en) 2014-10-09 2015-10-07 Indolinone compounds and uses thereof

Publications (2)

Publication Number Publication Date
IL251498A0 IL251498A0 (en) 2017-05-29
IL251498B true IL251498B (en) 2021-07-29

Family

ID=54337916

Family Applications (2)

Application Number Title Priority Date Filing Date
IL251498A IL251498B (en) 2014-10-09 2017-04-02 Indolinone compounds and their uses
IL284322A IL284322B2 (en) 2014-10-09 2021-06-23 Indolinone compounds and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL284322A IL284322B2 (en) 2014-10-09 2021-06-23 Indolinone compounds and their uses

Country Status (14)

Country Link
US (5) US9604927B2 (cg-RX-API-DMAC7.html)
EP (1) EP3204376B1 (cg-RX-API-DMAC7.html)
JP (2) JP6654197B2 (cg-RX-API-DMAC7.html)
KR (1) KR102482197B1 (cg-RX-API-DMAC7.html)
CN (2) CN107108580B (cg-RX-API-DMAC7.html)
AR (1) AR102222A1 (cg-RX-API-DMAC7.html)
AU (2) AU2015328121B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961781C (cg-RX-API-DMAC7.html)
EA (1) EA032644B1 (cg-RX-API-DMAC7.html)
IL (2) IL251498B (cg-RX-API-DMAC7.html)
MX (1) MX388564B (cg-RX-API-DMAC7.html)
NZ (1) NZ730585A (cg-RX-API-DMAC7.html)
TW (2) TWI705054B (cg-RX-API-DMAC7.html)
WO (1) WO2016057698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ723971A (en) 2012-04-12 2018-01-26 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
MX388564B (es) * 2014-10-09 2025-03-20 Oncternal Therapeutics Inc Compuestos de indolinona y usos de los mismos.
WO2017172368A1 (en) * 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN114569606B (zh) * 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
US20240139153A1 (en) * 2020-09-17 2024-05-02 Oklahoma Medical Research Foundation Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
EP1135123B1 (en) 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
CA2953987A1 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PL2154966T3 (pl) 2007-04-20 2014-03-31 Univ New York State Res Found Benzoimidazole i ich kompozycje farmaceutyczne
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
US20110218155A1 (en) * 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
MX368109B (es) 2008-10-21 2019-09-18 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
US8710068B2 (en) * 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
US20130259927A1 (en) 2012-04-02 2013-10-03 Gradalis, Inc. Ewing's Sarcoma Bifunctional shRNA Design
NZ723971A (en) 2012-04-12 2018-01-26 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
EP2968536B1 (en) * 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
CN103435606A (zh) * 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
WO2015061229A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
MX388564B (es) 2014-10-09 2025-03-20 Oncternal Therapeutics Inc Compuestos de indolinona y usos de los mismos.
WO2017172368A1 (en) 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN114569606B (zh) * 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途

Also Published As

Publication number Publication date
US20170065559A1 (en) 2017-03-09
EA032644B1 (ru) 2019-06-28
TWI750782B (zh) 2021-12-21
AU2020200631A1 (en) 2020-02-20
US20180256546A1 (en) 2018-09-13
US9895352B2 (en) 2018-02-20
EA201790445A1 (ru) 2017-09-29
US20160102055A1 (en) 2016-04-14
TWI705054B (zh) 2020-09-21
IL284322A (en) 2021-07-29
CA2961781C (en) 2023-10-03
JP2020059736A (ja) 2020-04-16
AU2015328121A1 (en) 2017-04-06
AU2015328121B2 (en) 2019-11-21
KR20170066609A (ko) 2017-06-14
CA2961781A1 (en) 2016-04-14
WO2016057698A1 (en) 2016-04-14
CN107108580B (zh) 2020-06-30
US9987251B2 (en) 2018-06-05
JP6795861B2 (ja) 2020-12-02
JP6654197B2 (ja) 2020-02-26
AR102222A1 (es) 2017-02-15
US20170066720A1 (en) 2017-03-09
TW202114986A (zh) 2021-04-16
IL284322B2 (en) 2023-08-01
US20220288023A1 (en) 2022-09-15
CN111777596A (zh) 2020-10-16
CN107108580A (zh) 2017-08-29
IL251498A0 (en) 2017-05-29
US9604927B2 (en) 2017-03-28
MX388564B (es) 2025-03-20
IL284322B1 (en) 2023-04-01
TW201629013A (zh) 2016-08-16
EP3204376B1 (en) 2023-04-19
AU2020200631B2 (en) 2022-03-24
MX2017003589A (es) 2018-08-15
NZ730585A (en) 2018-08-31
EP3204376A1 (en) 2017-08-16
JP2017532377A (ja) 2017-11-02
KR102482197B1 (ko) 2022-12-27

Similar Documents

Publication Publication Date Title
LT3215147T (lt) Neurologinį poveikį mažinantys norketamino junginiai ir būdai
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
AU361515S (en) Dishrack
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
AU362944S (en) Lapboard
IL284322A (en) Indolinone compounds and their uses
IL251107A0 (en) Compounds and methods
SG11201606199SA (en) Ketoprofen-containing poultice
DK3178931T3 (en) Anti-orai1-antistof
GB201419650D0 (en) Modified heterocyclase
DK3145380T3 (en) Toiletventilationssystem
GB2522661B (en) Context configuration
GB201420327D0 (en) Equine field nosebag
GB201408735D0 (en) Application coordination
AU5598P (en) Lanidaho Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5585P (en) Lanutah Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5597P (en) Lancalifornia Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
GB201407596D0 (en) New compounds and uses
GB201407599D0 (en) New compounds and uses
AU5289P (en) FLOMANFOP Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi